ACUTUS MEDICAL, INC.: diluted weighted-average shares

What this measure means

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

Exact concept: us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.

Coverage of this history

Selected reporting periods run from 2020-01-01 to 2024-12-31. The SEC response was captured on 2026-09-21.

Selected filing history

Related financial histories

• ACUTUS MEDICAL, INC.: total assets
• ACUTUS MEDICAL, INC.: total liabilities
• ACUTUS MEDICAL, INC.: stockholders equity
• ACUTUS MEDICAL, INC.: cash and cash equivalents
• ACUTUS MEDICAL, INC.: net income or loss
• ACUTUS MEDICAL, INC.: operating cash flow
• ACUTUS MEDICAL, INC.: capital expenditure payments
• ACUTUS MEDICAL, INC.: contract revenue excluding tax
• ACUTUS MEDICAL, INC.: financing cash flow
• ACUTUS MEDICAL, INC.: investing cash flow
• ACUTUS MEDICAL, INC.: retained earnings or deficit
• ACUTUS MEDICAL, INC.: basic weighted-average shares
• ACUTUS MEDICAL, INC.: basic earnings per share
• ACUTUS MEDICAL, INC.: diluted earnings per share
• ACUTUS MEDICAL, INC.: income tax expense or benefit
• ACUTUS MEDICAL, INC.: net property, plant and equipment
• ACUTUS MEDICAL, INC.: share-based compensation expense
• ACUTUS MEDICAL, INC.: operating income or loss
• ACUTUS MEDICAL, INC.: current assets
• ACUTUS MEDICAL, INC.: interest expense
• ACUTUS MEDICAL, INC.: current liabilities
• ACUTUS MEDICAL, INC.: current accounts payable
• ACUTUS MEDICAL, INC.: goodwill carrying amount
• ACUTUS MEDICAL, INC.: net finite-lived intangible assets
• ACUTUS MEDICAL, INC.: net current accounts receivable
• ACUTUS MEDICAL, INC.: operating expenses
• ACUTUS MEDICAL, INC.: net inventory
• ACUTUS MEDICAL, INC.: gross profit
• ACUTUS MEDICAL, INC.: selling, general and administrative expense
• ACUTUS MEDICAL, INC.: research and development expense
• ACUTUS MEDICAL, INC.: common shares outstanding
• ACUTUS MEDICAL, INC.: cash including restricted cash
• ACUTUS MEDICAL, INC.: additional paid-in capital
• ACUTUS MEDICAL, INC.: accumulated other comprehensive income or loss
• ACUTUS MEDICAL, INC.: total equity including noncontrolling interests
• ACUTUS MEDICAL, INC.: operating lease right-of-use asset
• ACUTUS MEDICAL, INC.: operating lease liability
• ACUTUS MEDICAL, INC.: long-term debt
• ACUTUS MEDICAL, INC.: gross property, plant and equipment
• ACUTUS MEDICAL, INC.: accumulated depreciation on property, plant and equipment
• ACUTUS MEDICAL, INC.: net intangible assets excluding goodwill
• ACUTUS MEDICAL, INC.: other noncurrent assets
• ACUTUS MEDICAL, INC.: other noncurrent liabilities
• ACUTUS MEDICAL, INC.: accrued current liabilities
• ACUTUS MEDICAL, INC.: prepaid expenses and other current assets
• ACUTUS MEDICAL, INC.: net deferred tax assets
• ACUTUS MEDICAL, INC.: pre-tax income or loss from continuing operations
• ACUTUS MEDICAL, INC.: profit or loss including noncontrolling interests
• ACUTUS MEDICAL, INC.: comprehensive income or loss
• ACUTUS MEDICAL, INC.: depreciation expense
• ACUTUS MEDICAL, INC.: amortization of intangible assets
• ACUTUS MEDICAL, INC.: nonoperating income or expense
• ACUTUS MEDICAL, INC.: current income tax expense or benefit
• ACUTUS MEDICAL, INC.: interest paid, net
• ACUTUS MEDICAL, INC.: operating lease payments
• ACUTUS MEDICAL, INC.: change in accounts receivable
• ACUTUS MEDICAL, INC.: change in inventories
• ACUTUS MEDICAL, INC.: change in accounts payable

Inspect the source

Entity

ACUTUS MEDICAL, INC. / CIK 0001522860

Captured

2026-09-21T17:20:27.662Z

SEC response SHA-256

75535e946915bf7b17c6ba4f04a76e277bb5e5b4fc056376e80048e3d38ac94b

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

• Get an API key and run your first validation
• Connect the MCP server to your coding assistant
• Inspect the ALPHAC engine on GitHub
• Read the MCP server source and integration examples

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001522860.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))